Celecoxib

Licensed by Pfizer 製品コードS1261 別名:SC 58635

カスタマーフィードバック(3)

  • Reduced hepatic lipid contents and alleviated liver injury in EC-AMPK mice treated with selective COX-2 inhibitors. Wild-type and EC-AMPK mice given a high fat diet were treated with vehicle, celecoxib or nimesulide for a period of 4 weeks. At the end of treatment, parameters including body weight and circulating glucose (A), serum triglyceride and cholesterol levels (B were measured and presented as percentage comparisons against those from vehicle-treated wild-type mice. *P < 0.05 versus wild-type mice treated with vehicle; #P < 0.05 versus EC-AMPK mice treated with vehicle, n = 3-5.

    Br J Pharmacol 2014 171(2), 498-508. Celecoxib purchased from Selleck.

    Breast cancer cells, wild type (WT) or anoikis resistant (AR) variants, were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined by trypan blue exclusion (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control. Upper inset pictures: HCC38 cells in 96 well plates were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined using a live-dead assay (red cells = dead; green cells = alive) (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control.

    J Cell Physiol 2014 10.1002/jcp.24843. Celecoxib purchased from Selleck.

  • Effect of celecoxib on the in vitro proliferation of BRAFV600E and NRASQ61R melanoma cell lines. a BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 3 × 103 per well in a 96-well plate and incubated with the indicated concentrations of celecoxib. Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, growth inhibition was determined by MTT assay. Data are expressed as mean percent of proliferation ± SD of treated cells as compared to untreated control cells. Mean percent of proliferation and SD were calculated from three independent experiments performed in triplicate. Difference between doses of celecoxib was calculated using unpaired t-test. *** indicate P < 0.001. b BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 4 × 105 per well in a 75 cm2 tissue culture flask and incubated with celecoxib (60 μM). Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, viability of cells was determined by trypan blue assay. Data are expressed as mean percentage of viable (negative) and death cells (positive) of treated cells as compared to untreated control cells. *** indicate P < 0.001

    J Transl Med, 2017, 15(1):46. Celecoxib purchased from Selleck.

製品安全説明書

COX阻害剤の選択性比較

生物活性

製品説明 セレコキシブは、40nMのIC50による選択的なCOX-2阻害剤です。
靶点
COX-2 [1]
(Sf9 cells)
40 nM
In vitro試験

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 MkXOSpVv[3Srb36gRZN{[Xl? M{DwNVAvOS1|MDFOwG0> MV60PEBp MnO0bY5lfWOnczDJR2FONTFiZYjwdoV{e2mxbjDvckBjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yw> MWGyOlUyOzF5Mh?=
H460 NW[xSIxOTnWwY4Tpc44hSXO|YYm= NWfxbpp1OC5zLUOwJO69VQ>? M3u0T|Q5KGh? M1vib4lv\HWlZYOgTWNCVS1zIHX4dJJme3Orb36gc44h[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVt NIHEN|IzPjVzM{G3Ni=>
HKESC-2 MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\PO2FXOjEEoN88US=> M1TGVlQ5yqCqwrC= NH\FbI1{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhUUN3MNMgeoFtfWW|IH;mJI95[WyrcHzheIlvyqB? MVGyOlQ4PDZ7Mx?=
CaES-17 NVjVdmRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjHZnd4OjEEoN88US=> MmfGOFjDqGkEoB?= NVLMWIl[e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKEmFNUFCpJZidHWnczDv[kBwgGGuaYDsZZRqdsLi NFvucWMzPjR5NE[5Ny=>
HKESC-2 NILWUpJCeG:ydH;zbZMhSXO|YYm= MVWyNOKh|ryP MoXxOFjDqGkEoB?= MoHHdoVlfWOnczDvfIFtcXCuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> NYnmPXBLOjZ2N{S2PVM>
CaES-17 MnHSRZBweHSxc3nzJGF{e2G7 MlXSNlDDqM7:TR?= MXu0POKhcMLi MkP2doVlfWOnczDvfIFtcXCuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> MmjqNlY1PzR4OUO=
A549 NHfFN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[xZY42NTF4MDFOwG0> MnnnOFjDqGkEoB?= M3;NcWROW09? NELHR5hKSzVyPUG2N{41KM7:TR?= MVWyOlQ3PDZ2Mx?=
HCC827 M4Tubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWS1MVE3OCEQvF2= NYjNOpdoPDkEoHlCpC=> M2Lx[WROW09? M{j1XWlEPTB;NkmuNkDPxE1? NYPQSGFZOjZ2NkS2OFM>
A549 NXqy[2dVSXCxcITvd4l{KEG|c3H5 MXq4NEDDvU1? NXeyfG9NPDkEoHlCpC=> MoS0SG1UVw>? NWPzXXdHcW6mdXPld{BieG:ydH;zbZM> NEfWWpozPjR4NE[0Ny=>
HCC827 M2W1bGFxd3C2b4Ppd{BCe3OjeR?= NGnrO2Y5OCEEtV2= NWHqbppFPDkEoHlCpC=> MmfXSG1UVw>? NX3VSo9KcW6mdXPld{BieG:ydH;zbZM> MlWxNlY1PjR4NEO=
SGC-7901/DDP NWPj[oR7TnWwY4Tpc44hSXO|YYm= Mn33NVDDqML3TR?= NVrkWVZqOjRiaB?= MmDTbY5pcWKrdIOgZ5lkdG:xeInn[Y5ie2VvMjDhcoQhWC2pbInjc5Bzd3SnaX6g[ZhxemW|c3nvci=> MnjsNlY1ODd4NUO=
SGC-7901  NVf1[o1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrkbZFoOjUEoHlCpC=> M{T6ZmlEPTB;MUG1MlA5KM7:TR?= NIHhdWMzPjRyN{[1Ny=>
SGC-7901/DDP M3H0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\mNlTDqGkEoB?= MnfkTWM2OD1|NT60OUDPxE1? MlLyNlY1ODd4NUO=
SGC-7901/DDP NGHue3hCeG:ydH;zbZMhSXO|YYm= MUGxNOKhyrWP M{fXTVI1KGh? M131eIlv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhid3n0bEBkcXOybHH0bY4> NWLuTVR{OjZ2MEe2OVM>
SGC-7901/DDP NE\l[HFHfW6ldHnvckBCe3OjeR?= NWnvd21GOTEEoNM1US=> MmjpNlQhcA>? NX70Z|Y2cW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4YhWC2pbInjc5Bzd3SnaX6geIhzd3WpaDDicI9kc2mwZzDFVFItKGGwZDDpcoFkfGm4YYTpcochWEuDIHHu[EBEWkWEwrC= M{LpNlI3PDB5NkWz
SGC-7901/DDP M361V2Z2dmO2aX;uJGF{e2G7 MX2xNOKhyrWP NH;qVXEzPCCq Mn3SZ4F2e2W|IHGgcYFzc2WmIHTlZ5Jm[XOnIHnuJJRp\SCuZY\lcEBw\iCEY3ytNkBxem:2ZXnu MoTKNlY1ODd4NUO=
H357 MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXG3MlUwOTBizszN NELUV4U1QCCq Mnr4SG1UVw>? MkLWbY5pcWKrdIOgZ4VtdCCpcn;3eIjDqGOxbXLpcoVlKHerdHigV4FjfXSxY3zhfC=> MlXvNlYxODl6N{S=
TAF MmXBSpVv[3Srb36gRZN{[Xl? MYexNOKhyrWP NEPkdHo4KGR? NV3HUGFw[W[oZXP0d{BVSU[|IHHkbIV{cX[nIIDyc5BmenSrZYO= NEHVWHUzPTl6N{GyOy=>
TAF MUDGeY5kfGmxbjDBd5NigQ>? M3LT[|ExyqEEtV2= MVuzNE0yOjBibXnu Ml;rdI9wemy7IHHm[oVkfHNiZFHreEBxcG:|cHjvdplt[XSrb36gZ49ve2WzdXXueEB1dyCHR1[gd4lodmGuaX7n NEjEenkzPTl6N{GyOy=>
TAF MnLZSpVv[3Srb36gRZN{[Xl? MW[xNOKhyrWP NWPFV|NIPDhiaB?= MUnpcoNz\WG|ZYOgSWdHWiCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? NGjyOGUzPTl6N{GyOy=>
PANC-1 NUfROldST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYqyNE83OC9zMECg{txO NF\tV|UzPC92OD:3NkBp NYTmcHVWcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MnPwNlU6PzNyNkK=
PANC-1 MY\GeY5kfGmxbjDBd5NigQ>? NFm3UpQzOC94MD:xNFAh|ryP NXfKWow2OjRiaB?= NV3tdXM1[XS2ZX71ZZR{KGOnbHygbY53[XOrb36gZY5lKG2rZ4LheIlwdiCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NWPMVWI1OjV7N{OwOlI>
HeLa  NHLX[FBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jBfFIxyqEQvF5CpC=> Mlr3NlTDqGh? M2PWUIVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:w MV:yOVc4ODR{Mx?=
SACC-83 NG\kO|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37EfVIxyqEQvF5CpC=> NFzqe3YzPMLiaB?= M{LxNoVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:w MV:yOVc4ODR{Mx?=
HeLa  MWnBdI9xfG:|aYOgRZN{[Xl? MmDMNlDDqM7:TdMg MWWyOOKhcA>? NX;kSHUz\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKGGyb4D0c5Nqew>? MnruNlU4PzB2MkO=
SACC-83 MnXDRZBweHSxc3nzJGF{e2G7 MkXkNlDDqM7:TdMg MlfVNlTDqGh? M2HzVoVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM> NFzZPYEzPTd5MESyNy=>
HeLa  NIq4[5lHfW6ldHnvckBCe3OjeR?= NF;J[Y0zOC92MD:4NEDPxE1? Ml:3NlTDqGh? NUHzNVR6fXC{ZXf1cIF1eyCSVFXOJJBienSrYXzsfUBjgSCrbnjpZol1cW6pIGPwNUwh[W6mIHHjeIl3[XSnczDQWGVPKGGwZDDpcoFkfGm4YYTld{BCU1R? NVfVUolrOjV5N{C0NlM>
SACC-83 MkHKSpVv[3Srb36gRZN{[Xl? Mm\DNlAwPDBxOECg{txO MonnNlTDqGh? MWn1dJJm\3WuYYTzJHBVTU5icHHyeIlidGy7IHL5JIlvcGmkaYTpcochW3BzLDDhcoQh[WO2aY\heIV{KFCWRV6gZY5lKGmwYXP0bZZifGW|IFHLWC=> MYWyOVc4ODR{Mx?=
HLCZ01 NIq3TZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;xOlDjiJN4MNMgxtVO M3;JSFQ5KGh? NULyWVF{TE2VTx?= NXXoW2VHcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NEPuS|MzPTd{NEi5PS=>
HLCZ01 MoOxSpVv[3Srb36gRZN{[Xl? MmOxOFDDqM7:TR?= NXnhT5RKOjRiaB?= MoPRSG1UVw>? NGHM[JhqdmO{ZXHz[ZMh[WOldX31cIF1cW:wIH;mJGcxN0dzLYDoZZNmKGOnbHzzJINwdWKrbnXkJJdqfGhiSV\OMe6y MVGyOVczPDh7OR?=
HLCZ01 MoOwRZBweHSxc3nzJGF{e2G7 MorlOFDDqM7:TR?= NEHZPJczPCCq NWTlfVE{TE2VTx?= MmS2[Y5p[W6lZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiSV\OMe6y MVmyOVczPDh7OR?=
HLCZ01 NYfPUo5bTnWwY4Tpc44hSXO|YYm= MUm0NOKh|ryP NIfGR4ozPCCq NWDzeXJrTE2VTx?= M4rCVolv[3KnYYPld{BVWkGLTDDlfJBz\XO|aX;uJINwdWKrbnXkJJdqfGhiSX70[ZJn\XKxbj5OtS=> NXnOfFFDOjV5MkS4PVk>
MGC803 MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFq5TlMxNTZyIN88US=> NFnZeHQ4OiCq MoTvTWM2OD12Nz6yOgKBkcLz4pEJOk41OyEQvF2= M3fwfVI2PzBzM{e4
SGC7901 MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzONE03OCEQvF2= NHXi[3Q4OiCq MYXJR|UxRTR|LkWz5qCKyrIkgJm1MlEzKM7:TR?= NV7COllDOjV5MEGzO|g>
MGC803 NHHZbpdHfW6ldHnvckBCe3OjeR?= NYW4OmZjPDEEoN88US=> MUS4M|E3NzJ2IHi= MlW5eZBz\We3bHH0d{BE[mxvYjDlfJBz\XO|aX;u MkO5NlU4ODF|N{i=
SGC7901 MoW2SpVv[3Srb36gRZN{[Xl? M{XjXVQxyqEQvF2= M{Dzc|gwOTZxMkSgbC=> MmfFeZBz\We3bHH0d{BE[mxvYjDlfJBz\XO|aX;u M4XhTlI2PzBzM{e4
MCF-7  NIXjUpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjZeIEyNzFyIN88US=> NFjjdFQ4OiCq MXPEUXNQ M2faeYVvcGGwY3XzJINidGOrdILpc4wucW6mdXPl[EBk\WyuIHfyc5d1cCCrbnjpZol1cW:w MYmyOVY3PzVzMB?=
MDA-MB-231  MlTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jGS|EwOTBizszN NV;EfJh2PzJiaB?= M3PaZmROW09? NVzCTWI3\W6qYX7j[ZMh[2GuY3n0dolwdC2rbnT1Z4VlKGOnbHyg[5Jwf3SqIHnubIljcXSrb36= NXvMVVVROjV4Nke1NVA>
MDA-MB-231 M2K4OmZ2dmO2aX;uJGF{e2G7 MYqwMVQxKML3TR?= NG\4[Yg1NTJ2IHi= MljHbY5kemWjc3XzJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbjDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MVOyOVU5PzN{OR?=
MCF-7 NYrHZ2w{TnWwY4Tpc44hSXO|YYm= NGn3cZUxNTRyINM1US=> MYW0MVI1KGh? NESyfIJmdmijbnPld{B1cGViZX\m[YN1eyCxZjDUVGEhd25iQVLDS|Ih\XiycnXzd4lwdsLi NXvKRlBMOjV3OEezNlk>
MCF7-MX  M2jNR2Z2dmO2aX;uJGF{e2G7 M{[5bVAuPDBiwsXN NULBUpFIPC1{NDDo NX;iW3A{\W6qYX7j[ZMhfGinIHXm[oVkfHNib3[gWHBCKG:wIFHCR2czKGW6cILld5Nqd28EoB?= NGDRfGczPTV6N{OyPS=>
MDA-MB-231 NVnvXYhTTnWwY4Tpc44hSXO|YYm= NF:wNlkxNTRyINM1US=> MkO0OE0zPCCq NHPNc2l{fGmvdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKEGEQ1eyJJVxKHSxIESuNlchfGmvZYOgeI8h[2:wdILvcEBt\X[nbDDifUAyOiCqwrC= MV[yOVU5PzN{OR?=
A2780 MUfGeY5kfGmxbjDBd5NigQ>? MknCOU8yOC9zNTFOwG0> NELvbVk1QCCq MU\k[YNz\WG|ZYOgR495NTJiZYjwdoV{e2mxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3zE[lI2PDJ2OEm4
SKOV3  MYDGeY5kfGmxbjDBd5NigQ>? MYC1M|ExNzF3IN88US=> NICzR5U1QCCq MmTy[IVkemWjc3XzJGNwgC1{IHX4dJJme3Orb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NHjZc2wzPTR{NEi5PC=>
A2780 M4jaRmZ2dmO2aX;uJGF{e2G7 Mo\0OU8yOC9zNTFOwG0> M3nyXlQ5KGh? NUSzPYNW\WyndnH0[ZMhfGinIHX4dJJme3Orb36gc4YhTS2lYXTo[ZJqdiCjbnSgb4Vz[XSrbh?= NXnSdml1OjV2MkS4PVg>
SKOV3  NEPGNYJHfW6ldHnvckBCe3OjeR?= MVq1M|ExNzF3IN88US=> MWC0PEBp M1LPOoVt\X[jdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGUu[2GmaHXybY4h[W6mIHvldoF1cW5? M2e1UVI2PDJ2OEm4
A2780 MYXGeY5kfGmxbjDBd5NigQ>? NVnv[VVsPS9zMD:xOUDPxE1? MYW0PEBp MXXk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUk1k[WSqZYLpckBidmRiVnnt[Y51cW5? M4nxXlI2PDJ2OEm4
SKOV3  MlzqSpVv[3Srb36gRZN{[Xl? MX:1M|ExNzF3IN88US=> M3LmbFQ5KGh? Ml[y[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJG4u[2GmaHXybY4h[W6mIG\pcYVvfGmw NYq3NoFUOjV2MkS4PVg>
A2780 MUDGeY5kfGmxbjDBd5NigQ>? M2LmU|UwOTBxMUWg{txO MnO4NUBp Mn;PbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M{fXcVI2PDJ2OEm4
SKOV3  NYmxd2JJTnWwY4Tpc44hSXO|YYm= MmjiOU8yOC9zNTFOwG0> NEL2dYQyKGh? MWXpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gdE1CU1RiYX7kJJAuTVKNIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MkfQNlU1OjR6OUi=
HCT-15 M4DjZmZ2dmO2aX;uJGF{e2G7 M3:5WlExNTVyIN88US=> MV22MVM3KGh? NHiyTI5qdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy M1vhfFI2OjF6MEK4
HT-29  NVqwWnJpTnWwY4Tpc44hSXO|YYm= Mn7ONVAuPTBizszN MYi2MVM3KGh? M1\1U4lv\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gR29ZNTJiaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MoT0NlUzOThyMki=
HSC3  MkLQR4VtdCCYaXHibYxqfHliQYPzZZk> Ml\RNQKBmzRyIN88US=> NUPZUo1PPDhiaB?= MoD0TWM2OD1{NT61xtEyNjd6MDFOwG0> NWHLXZRZOjVzOUi3PFk>
HSC3  MmXTRZBweHSxc3nzJGF{e2G7 MUKyOUDPxE1? M1PYbVQ5KGh? Mnq0bY5lfWOnczDhdI9xfG:|aYO= MYeyOVE6QDd6OR?=
HSC3  NHrHTlNHfW6ldHnvckBCe3OjeR?= M335[|I2KM7:TR?= NU\IUGJpPDhiaB?= NI[1N3BmgGirYnn0d{B{cWewaX\pZ4FvfGy7IILl[JVk\WRibXnndoF1cW:wIHPvcYJqdmWmIIfpeIghS0WW MnvTNlUyQTh5OEm=
HSC3  M4DqcmZ2dmO2aX;uJGF{e2G7 NHPNWJAzPSEQvF2= MlHBOFghcA>? MV7pcohq[mm2czDIV2M{KGOnbHygbY53[XOrb36gZ49u[mmwZXSge4l1cCCFRWS= M2DT[|I2OTl6N{i5
HSC3  NHLTdplHfW6ldHnvckBCe3OjeR?= NIX5TIUzPSEQvF2= NYjYN5FWPzJiaB?= Mn2z[IVkemWjc3XzJG1OWC1{IHHu[EBOVVBvOTDwdo91\Wmwc9Mg MXuyOVE6QDd6OR?=
201T  M4Oye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7XO|IhcA>? MojDSG1UVw>? NXPLWGVvUUN3ME20PE43KML3TR?= M4LJUFI2ODV5OUSx
273T NIPtWoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELiZno4OiCq Ml;6SG1UVw>? NXTM[3ZbUUN3ME24NE42KML3TR?= MnfvNlUxPTd7NEG=
Hep-2 NHi2c|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXaN|AwPTBxMUCwJO69VQ>? NED3U|IyOi9{ND:zOk81QCCq M2rEZ2ROW09? NEjvToVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M1\ESVI1QTl6NU[0
Hep-2 NYm3NJBTSXCxcITvd4l{KEG|c3H5 Ml7hOVAh|ryP M4jvelAuPDhiaB?= NIfVVGVFVVOR Mnz1bY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lJIRmeGWwZHXueEBu[W6wZYK= M2HzN|I1QTl6NU[0
Hep-2 M3\zUmZ2dmO2aX;uJGF{e2G7 NEDubXg2OCEQvF2= MVmwMVQ5KGh? NYLPT4FCTE2VTx?= NYjWd5hkemWmdXPld{B1cGVidHXsc41memG|ZTDhZ5Rqfmm2eTDndoFlfWGubIm= NI\lWo8zPDl7OEW2OC=>
Hep-2 NX3sRlFlTnWwY4Tpc44hSXO|YYm= NHnud|E2OCEQvF2= NYLXeY1OOC12ODDo M{fQVGROW09? MnHu[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiaGTFVnQ> MYeyOFk6QDV4NB?=
SGC-7901 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\mdnkyOC93MD:xNFAh|ryP NVnqfoZxOjRxNEivO|IhcA>? NGnzZZJFVVOR MYnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MXGyOFk6Ojl3OB?=
MKN-45 MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfPNVAwPTBxMUCwJO69VQ>? MnrRNlQwPDhxN{KgbC=> NVK3U2ZJTE2VTx?= NH7qV25qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MojYNlQ6QTJ7NUi=
SGC-7901 NEjlTnFHfW6ldHnvckBCe3OjeR?= MnKwNVAwPTBxMUCwJO69VQ>? NYjVNo9EPDhiaB?= NVjnPG8{TE2VTx?= NYrsRWF2\G:5boLl[5Vt[XSnczD0bIUhdVKQQTDlfJBz\XO|aX;uJIxmfmWuczDv[kBEV1hvMjDhcoQhWEOQQTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M{jMb|I1QTl{OUW4
MKN-45 M{Pod2Z2dmO2aX;uJGF{e2G7 NH:2VGgyOC93MD:xNFAh|ryP MknPOFghcA>? NXjj[FFLTE2VTx?= M4jlPYRwf26{ZXf1cIF1\XNidHjlJI1TVkFiZYjwdoV{e2mxbjDs[ZZmdHNib3[gR29ZNTJiYX7kJHBEVkFiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NX3Zb3l2OjR7OUK5OVg>
C666-1 NILvW|BEgXSxdH;4bYNqfHliQYPzZZk> M1zESlIxNThyIN88US=> MYiyOEBp MULk[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg MkK4NlQ5PTR6M{i=
CNE-1 Mk\XR5l1d3SxeHnjbZR6KEG|c3H5 MYOyNE05OCEQvF2= MXeyOEBp Mn3r[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> MoC3NlQ5PTR6M{i=
CNE-2 MXLDfZRwfG:6aXPpeJkhSXO|YYm= NH;w[GwzOC16MDFOwG0> M{fmO|I1KGh? MVTk[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg NYqwcnhSOjR6NUS4N|g>
C666-1 NHzqfFhEgXSxdH;4bYNqfHliQYPzZZk> MofvOlAh|ryP M{HFblch\A>? NHPvdJNmdmijbnPld{Bz[WSrYYTpc44h[3m2b4TvfIlkcXS7IITodo92\2hiQ1;YMVIu\GWyZX7k[Y51KG2jbn7ldi=> MXWyOFg2PDh|OB?=
CNE-1 NVH5O2pzS3m2b4TvfIlkcXS7IFHzd4F6 NYLaOZNiPjBizszN MknFO{Bl MoXi[Y5p[W6lZYOgdoFlcWG2aX;uJIN6fG:2b4jpZ4l1gSC2aILveYdpKEORWD2yMYRmeGWwZHXueEBu[W6wZYK= MkK5NlQ5PTR6M{i=
SNU-1041 MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGO0RmExNTRyIN88US=> M4rQelQ5KGh? NE\0bWNqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M3PXUlI1Pjl{N{Cz
SNU-1041 NWfTZ4h2TnWwY4Tpc44hSXO|YYm= NF[5cWczOC9|MDFOwG0> NXPsTWRSPCCq M4PYPIlv\HWlZYOg[ZhxemW|c3nvckBw\sLiQ1jPVEwhT1KSN{lCpIFv\MLiWFLQNeKh[XRidHjlJHJPSSCuZY\lcOKh Mlv4NlQ3QTJ5MEO=
SNU-1041 NGPxWlhHfW6ldHnvckBCe3OjeR?= MljSNE01OCEQvF2= MorxOEBp NFPqUph2eC2{ZXf1cIF1\XNiQ1jPVOKh[W[2ZYKgeJJm[XSvZX70JJdqfGhiaHnnbEBkd26lZX70doF1cW:wcx?= Mlm3NlQ3QTJ5MEO=
SGC-7901 MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;ISGVjPTBvMUK1JO69VQ>? NIK2[IkzPC92OD:3NkBp NF7OVohqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MojwNlQ3PzZ|OUS=
SGC-7901 NYnzNpZ6SXCxcITvd4l{KEG|c3H5 MmXxNVAxKM7:TR?= MWm3NkBp M3npNYlv\HWlZYOgZZBweHSxc3nz NEfvXXEzPDZ5NkO5OC=>
SGC-7901 MnnwSpVv[3Srb36gRZN{[Xl? MWC3OU8yODBxMUK1JO69VQ>? NX3DTnB7OjRxNEivO|IhcA>? M4LoVolv[3KnYYPld{Bk[XOyYYPlMVgh[W6mID25JI1TVkFiZYjwdoV{e2mxbjDpckBjd3SqIITpcYUh[W6mIHTvd4UhdWGwbnXy MVSyOFY4PjN7NB?=
LMeC  NIGwPGdHfW6ldHnvckBCe3OjeR?= MWGyNE82OCEQvF2= MWO0PEBp NXjDeW1O\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEORWD2yJJBzd3SnaX6= Ml\RNlQ3PTZ5NE[=
CMeC-1 M4rKPGNmdGxiVnnhZoltcXS7IFHzd4F6 NXTxe|FVOjBxNUCg{txO MmSwOFghcA>? MXLpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M2Cwb|I1PjV4N{S2
LMeC NEe2c2dE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2\wV|IxNzVyIN88US=> MmXNOFghcA>? Mn;ubY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NUnJRXE5OjR4NU[3OFY>
CMeC-1 MnzwSpVv[3Srb36gRZN{[Xl? MkjJNlAwPTBizszN NXzwTY5YPDhiaB?= M3\PZYlv\HWlZYOgS|EuWyCjcoLld5Q> MknnNlQ3PTZ5NE[=
LMeC Mki5SpVv[3Srb36gRZN{[Xl? MlPMNlAwPTBizszN NXzad|JmPDhiaB?= NXTTU3JNcW6mdXPld{BIOS2VIHHydoV{fA>? M{DUNFI1PjV4N{S2
CMeC-1 NXfhOmU4TnWwY4Tpc44hSXO|YYm= MlfwNlAwPTBizszN M3ztUFQ5KGh? Mkfw[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZiY4njcIlvKERzIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M1XwTFI1PjV4N{S2
LMeC M2DRW2Z2dmO2aX;uJGF{e2G7 NXPLTXJCOjBxNUCg{txO M33sRlQ5KGh? NIPH[INl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjfYNtcW5iREGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MUOyOFY2Pjd2Nh?=
CMeC-1 M376[WZ2dmO2aX;uJGF{e2G7 NUPudXI2OjBxNUCg{txO NUntRpU1PDhiaB?= NEfBb|BqdmS3Y3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v MlLONlQ3PTZ5NE[=
LMeC MlzESpVv[3Srb36gRZN{[Xl? M1z3NlIxNzVyIN88US=> NWnJVmRmPDhiaB?= NHq2OFRqdmS3Y3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v MUWyOFY2Pjd2Nh?=
OVCAR-3 NHz6[GNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MV2xNEDDvU1? MkD4NUBp NFnnWINmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQhd3[jcnnhckBk[W6lZYKgZ4VtdCCmZXH0bOKh NHfVbZgzPDV{MEKyOy=>
OVCAR-3 M4PEXmFxd3C2b4Ppd{BCe3OjeR?= M3rW[|ExKML3TR?= NH;a[pIyKGh? M4XYe5Bzd22xdHXzJJBi[2yrdHH4[YwucW6mdXPl[EBieG:ydH;zbZPDqA>? NFvIcYozPDV{MEKyOy=>
OVCAR-3 NX7GTopRTnWwY4Tpc44hSXO|YYm= MkXyNVAhyrWP MXuxJIg> MVvlcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmNToEoB?= MX:yOFUzODJ{Nx?=
OVCAR-3 NEn4PIRHfW6ldHnvckBCe3OjeR?= M{XDeFExKML3TR?= NYP1bGs2OSCq M4rDdIRwf25vcnXneYxifGW|IF7GMe67SiCjY4TpeoF1cW:wIHnu[JVk\WRiYomgdIFkdGm2YYjlcC=> MlXXNlQ2OjB{Mke=
OVCAR-3 M1LDc2Z2dmO2aX;uJGF{e2G7 Mm\1NVAhyrWP MWCxJIg> NH\Se4xqdmirYnn0d{Bx[WOuaYThfIVtNWmwZIXj[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NY\p[45IOjR3MkCyNlc>
CF33 NXXpc4xmTnWwY4Tpc44hSXO|YYm= MVmxNFAh|ryP Mk\ENlQhcA>? M2TIeolv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gR29ZNTJicILveIVqdiCneIDy[ZN{cW:w MnjuNlQ2ODN5OEK=
CF33 MoDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYKxNE0yODBizszN MUOwMVQh\A>? NE\mWnVqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NW[yWm9GOjR3MEO3PFI>
CF33 MVjGeY5kfGmxbjDBd5NigQ>? MV:xNE0yODBizszN NFKwbo81NTJ2IHi= NHvVWWNl\WO{ZXHz[ZMh[2WubIOgbY4hfGinIGOgdIhie2ViYX7kJIlv[3KnYYPld{Bk\WyuczDpckBIOC:JMTDhdpJme3R? M{H0fVI1PTB|N{iy
LNCaP M1mwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3P3NFIwPS9zMDFOwG0> NE[1VY06PiCq NHP2b4pqdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5JINwdWKrbnXkJJdqfGhiYYTvdpZie3SjdHnu M1;4U|I1Ojl4OUe4
LNCaP M1[0SmFxd3C2b4Ppd{BCe3OjeR?= MkK5Nk82NzFyIN88US=> MYC5OkBp NHLBN|JqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> MkjINlQzQTZ7N{i=
PC-3  NV;mZ3V6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrQ[Hd6OC13MDFOwG0> MnjJOFjjiImq NVLSVXF3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NXLMflVsOjRzMke4PFI>
PC-3  MU\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MW[wMVExOCEQvF2= NYjnNmhVPzJiaB?= M2XOSIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NX\jWYNCOjRzMke4PFI>

... Click to View More Cell Line Experimental Data

In vivo試験 Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

プロトコル(参考用のみ)

キナーゼアッセイ:[1]
+ 展開

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
細胞アッセイ: [2]
+ 展開
  • 細胞株: HNE1 and CNE1-LMP1
  • 濃度: 0-75 μM
  • 反応時間: 48 hours
  • 実験の流れ: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (参考用のみ)
動物実験:[1]
+ 展開
  • 動物モデル: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • 製剤: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
  • 投薬量: ≤200 mg/kg
  • 投与方法: Administered via p.o.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water <1 mg/mL
体内 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL

* <1 mg/mlは製品が微弱に溶解する或いは溶解しないことを示します。
* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 381.37
化学式

C17H14F3N3O2S

CAS No. 169590-42-5
保管
in solvent
別名 SC 58635

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT02845336 Recruiting Thyroid Eye Disease Johns Hopkins University January 31, 2017 Phase 2
NCT02054104 Suspended Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 27, 2014 Phase 1|Phase 2
NCT01143545 Completed Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 26, 2010 Phase 1
NCT01313429 Completed Sarcoma|Melanoma|Epithelial Malignancies|Pleural Malignancies National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 23, 2011 Phase 1
NCT02160301 Suspended Post Operative Pain Control University of North Carolina, Chapel Hill November 2017 Phase 4

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • 回答:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX信号経路図

COX Inhibitors with Unique Features

相関COX製品

Tags: Celecoxibを買う | Celecoxib ic50 | Celecoxib供給者 | Celecoxibを購入する | Celecoxib費用 | Celecoxib生産者 | オーダーCelecoxib | Celecoxib化学構造 | Celecoxib分子量 | Celecoxib代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID